0000000000704256

AUTHOR

Kaya Miah

showing 1 related works from this author

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results f…

2021

Abstract Background: Treatment regimens including a proteasome inhibitor, immunomodulating agent and a monoclonal antibody (moAb) play an emerging role in the treatment of newly-diagnosed multiple myeloma (NDMM). This multicenter phase III trial of the German-speaking Myeloma Multicenter Group (GMMG HD6) investigated the addition of the anti-SLAMF7 moAb elotuzumab to lenalidomide / bortezomib / dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible NDMM. Patients and Methods: Patients were equally randomized into four treatment arms, stratified by International Staging System (ISS). Treatment consisted of four 21-da…

Oncologymedicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologyNewly diagnosedmedicine.diseaseBiochemistryInternal medicineMedicineAutologous transplantationElotuzumabbusinessMultiple myelomaBortezomib/dexamethasonemedicine.drugLenalidomideBlood
researchProduct